← Feed

$PCSA

6 theses
bullish 100%neutral 0%bearish 0%
Avg return (6m)
—
Win rate (6m)
— (0 resolved)
1d3d1w1m3m6m1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices delayed ~15 min · refreshed 25m ago
$PCSAr/pennystocksStock Infobullish
u/CommitteeLocal9703 · 338d agono track record yet

$PCSA: Catalyst Watch: Possible Licensing News by Tomorrow + Earnings on Oct 29

Processa Pharmaceuticals' 120-day licensing agreement window with Intact Therapeutics ends October 15, and a signed deal would bring $2.5M upfront plus up to $452.5M in potential milestones and royalties. The low-float micro-cap setup and upcoming earnings on October 29 create near-term catalysts that could drive a significant re-rating if the deal closes and validates the strategy of monetizing non-core assets.

Now $1.9525m ago
original post →
$PCSAr/pennystocksBullishbullish
u/Specialist_Self4672 · 342d ago2 prior · awaiting results

Listen up – PCSA’s 120-day deadline is next week (Oct 15th)

PCSA's 120-day deadline for finalizing a binding $454M licensing deal with Intact Therapeutics expires October 15th. Two of three likely outcomes (deal completion or extension with additional payment) are bullish, while a walk-away is least probable. The stock is consolidating on low volume in anticipation of this catalyst.

Now $1.9525m ago
original post →
$PCSAr/pennystocksBullishbullish
u/Specialist_Self4672 · 343d ago2 prior · awaiting results

$PCSA has a potential $454M+ licensing deal on the table

PCSA signed a binding term sheet with Intact Therapeutics for PCS12852 worth over $454M in potential milestone and royalty payments, creating a significant disconnect between the microcap's current valuation and upside if the deal closes and the drug progresses through trials and commercialization.

Now $1.9525m ago
original post →
$PCSAr/pennystocksBullishbullish
u/Specialist_Self4672 · 344d ago2 prior · awaiting results

$PCSA – Processa Pharmaceuticals – Why I’m Bullish AF.🚀

Stock exhibits a repeated intraday dip-and-rebound pattern with support holding on higher timeframes. The consistent absorption of dips and subsequent gap-ups suggest institutional buying, indicating further upside potential.

Now $1.9525m ago
original post →
$PCSAr/pennystocksStock Infobullish
u/Soft_Ant4357 · 345d agono track record yet
“holding a small position with a $.30 average”

PSCA - A Biopharmaceutical - The Next Runner?

Processa Pharmaceuticals is a small-cap biopharmaceutical with pipeline catalysts in 2025-2026, including Phase 2/3 NGC-Gemcitabine trials, FDA discussions on PCS499, and investor conferences. The company has sufficient cash runway (7-9 months) to reach key milestones without near-term dilution threats, positioning it as a potential runner for early-stage biotech investors.

Now $1.9525m ago
original post →
$PCSAr/pennystocksDDbullish
u/BrightLengthiness853 · 345d agono track record yet

$PCSA...low float biotech waking up ahead of a possible $450M+ licensing deal

Processa Pharmaceuticals is poised for a re-rating on a potential $452.5M licensing deal with Intact Therapeutics for its gastroparesis drug. The binding term sheet, combined with a tiny free float and recent unexplained volume spike, suggests early insider positioning ahead of an announcement that could unlock significant near-term cash and eliminate dilution concerns.

Now $1.9525m ago
original post →

End of results.